Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 4/20 | 0.32 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
| ▸ | MMP7 | P09237 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768652 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL14038029 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL9980016 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL330041 | 1.00 | — | — | |
| SCHEMBL28826 | 1.00 | — | — | |
| Iodide SCHEMBL11077837 | 0.97 | — | — | |
| SCHEMBL28278 | 0.96 | — | — | |
| SCHEMBL18571635 | 0.91 | MMP1 (0.37) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL29224 | 0.89 | — | — | |
| SCHEMBL23952727 | 0.86 | ACHE (0.46) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529722-B | High-elastic modulus epoxy resin composition and steel-bonding structural adhesive | 湖南瑞弗斯科技发展有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119529722-A | High-elastic modulus epoxy resin composition and steel-bonding structural adhesive | 湖南瑞弗斯科技发展有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-11660355-B2 | Engineered extracellular vesicles for enhanced tissue delivery | CEDARS-SINAI MEDICAL CENTER (US) | 2023-05-30 | — | — | US | disclosed |
| US-20200316226-A1 | ENGINEERED EXTRACELLULAR VESICLES FOR ENHANCED TISSUE DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660355-B2 | Engineered extracellular vesicles for enhanced tissue delivery | EXOSC5, EXOSC10, SDCBP | CHRM5 4425/4885CYP1A2 4785/4885ADRA2C 3764/4885 |
| US-20200316226-A1 | ENGINEERED EXTRACELLULAR VESICLES FOR ENHANCED TISSUE DELIVERY | EXOSC5, EXOSC10, SDCBP | CHRM5 4425/4885CYP1A2 4785/4885ADRA2C 3764/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | CHRM5 3061/4885CYP1A2 1547/4885ADRA2C 492/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | CHRM5 1334/4885CYP1A2 855/4885ADRA2C 1097/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | CHRM5 2403/4885CYP1A2 3946/4885ADRA2C 985/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | CHRM5 3619/4885CYP1A2 1483/4885ADRA2C 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.